Abstract 3914: BTK and MALT1 are critical for cell adhesion and dissemination in mantle cell lymphoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3914
Abstract: Bruton’s tyrosine kinase (BTK) is a great target in mantle cell lymphoma (MCL). This is evident by multiple FDA approvals of covalent BTK inhibitors (BTKi, e.g. ibrutinib, acalabrutinib and zanubrutinib) and recent exciting clinical data… read more here.
Keywords: cell; malt1; growth; btki ... See more keywords
Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm12030376
Abstract: Mantle cell lymphoma (MCL) is a rare mature B-cell non-Hodgkin lymphoma (B-NHL) with historically poor outcomes. Virtually all patients will eventually experience refractory or relapsed (R/R) disease, with a virulent course of resistance and serial… read more here.
Keywords: btki; cell lymphoma; relapsed refractory; mantle cell ... See more keywords